signs of taming Delta

 

Pfizer seeks U.S. approval for COVID vaccine booster

Aug 25 (Reuters) - Pfizer Inc (PFE.N) on Wednesday said a booster dose of its two-shot COVID-19 vaccine spurs a more than threefold increase in antibodies against the coronavirus, as the company seeks U.S. regulatory approval for a third injection.

That eight-month gap is likely to be narrowed to six months, the Wall Street Journal reported on Wednesday.

 

Israel’s COVID-19 vaccine boosters show signs of taming Delta

On July 30, it began administering a third dose of the Pfizer/BioNtech vaccine to people over 60, the first country to do so. On Thursday it expanded eligibility to 40-year-olds and up whose second dose was given at least 5 months prior, saying the age may drop further.
　In the past 10 days, the pandemic is abating among the first age group, more than a million of whom have received a third vaccine dose, according to Israeli health ministry data and scientists interviewed by Reuters.

ファイザーの3回目のワクチンで抗体が３．３倍に。

イスラエルでは３回目うった人たちの間ではパンデミックは沈静化　６０代以上から初めて４０代以上の人たちへの接種を始めると。

２回目からの期間は当初８ヶ月と言われていたが、アメリカでは６ヶ月、イスラエルでは最低５ヶ月となるもよう。